New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies
Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Feb 21, 2022
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new treatment approach using monoclonal antibodies to fight BK virus (BKV) infection, which can be a serious issue for people who have received organ transplants. Currently, there are no specific antiviral treatments available for BKV, making it important to find effective new strategies to help patients. The trial is not yet recruiting participants, but it aims to include adults aged 65 to 74 who are positive for the BK virus and willing to participate in research.
To be eligible for this trial, participants must be adults who have tested positive for the BK virus and are able to consent to join the study. However, individuals who are under guardianship or curatorship, those who do not wish to participate in research, or anyone who is deprived of liberty will not be included. If you or someone you know is interested in this trial, you can expect to learn more about how this new treatment might help manage BK virus infections in transplant recipients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BK positive
- • adult
- • ok to participed to research
- Exclusion Criteria:
- • under guardianship
- • under curatorship
- • opposed to research
- • deprived of liberty
About University Hospital, Strasbourg, France
The University Hospital of Strasbourg, France, is a leading academic medical center renowned for its commitment to advancing healthcare through innovative clinical research and patient-centered care. As a prominent sponsor of clinical trials, the institution collaborates with a diverse range of healthcare professionals and research teams to explore cutting-edge therapies and treatment modalities. With state-of-the-art facilities and a multidisciplinary approach, the University Hospital of Strasbourg plays a pivotal role in translating scientific discoveries into effective clinical applications, contributing significantly to the advancement of medical knowledge and improved patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Strasbourg, , France
Patients applied
Trial Officials
Samira FAFI-KREMER
Principal Investigator
University Hospital, Strasbourg, France
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials